The startup has developed a nanomedical platform that utilizes targeted nanoparticles to selectively remove disease-causing molecules from the bloodstream within minutes. This technology provides a new treatment option for major diseases, enhancing patient safety and efficacy compared to traditional methods.
Funding
$37M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LVFounders
Product
Problem
Many diseases are caused or exacerbated by the presence of specific pathogenic molecules circulating in the bloodstream. Current treatments for removing these molecules are often non-selective, inefficient, or have significant side effects.
Solution
NaNotics has developed a nanomedical platform designed to selectively remove disease-causing molecules directly from the bloodstream. The technology utilizes targeted nanoparticles engineered to bind to and neutralize specific pathogenic molecules. This approach aims to provide a more targeted and efficient treatment option compared to traditional methods, potentially enhancing patient safety and efficacy. By directly addressing the molecular drivers of disease, NaNotics seeks to offer a novel therapeutic intervention for a range of conditions.
Target Audience
The primary target audience includes patients suffering from diseases caused or exacerbated by specific molecules in the bloodstream, as well as clinicians seeking more targeted and effective treatment options.
Features
- Nanoparticles engineered for high-affinity binding to specific disease-causing molecules
- Modular design allows for targeting of a wide range of circulating pathogens and toxins
- Rapid removal of target molecules from the bloodstream
- Enhanced selectivity minimizes off-target effects and improves patient safety
- Potential for use in a variety of disease indications